Changes in Hong Kong stocks | Conoa-B (02162) rose more than 9% intraday TSLP/IL-13 dual-antibody CM512 to be included in breakthrough treatment

The Zhitong Finance App learned that Conoa-B (02162) rose more than 9% in the intraday period. As of press release, it had risen 6.69% to HK$86.15, with a turnover of HK$468 million.

According to the news, on July 15, Connor TSLP/IL-13 dual antibody CM512 will be included in breakthrough treatment to treat chronic sinusitis with nasal polyps. At present, CM512 has completed the Phase II clinical study on chronic sinusitis with nasal polyps. At the same time, it is also promoting clinical research on various indications such as atopic dermatitis, asthma, chronic obstructive pulmonary disease, and chronic spontaneous urticaria, with a broad layout. The proposed inclusion of breakthrough treatment varieties will speed up the CM512 follow-up review and approval process and shorten the marketing cycle.

Huayuan Securities pointed out that in the second half of the year, Connoya will welcome several pipelines with key data and reporting points: CMG901 is expected to disclose key data on later-line gastric cancer and simultaneously advance FDA reporting; CM336 plans to submit a domestic listing application (BLA); and the amount of health insurance dividends based on sipuximab is expected to continue to be realized.